As bad as it may look on the charts, Moderna’s (NASDAQ: MRNA) post-COVID let-down and market reset are over. The company ...

Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Below is a chart showing MRNA's trailing twelve month trading history, with the $38 strike highlighted in orange: Edison International (Symbol: EIX) options are showing a volume of 36,029 ...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines ...

Why Goldman Cut Its Rating on MRNA Earlier this month, Moderna reduced its 2025 revenue guidance, based on relatively weak demand for its Covid and RSV shots. Why Moderna Inc. (MRNA) is Skyrocketing?

In the following chart, we are able to follow the development ... had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which ...